Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.96 USD
Change Today -0.01 / -0.34%
Volume 402.4K
CRIS On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

curis inc (CRIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/17/15 - $3.50
52 Week Low
12/18/14 - $1.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CURIS INC (CRIS)

curis inc (CRIS) Related Businessweek News

No Related Businessweek News Found

curis inc (CRIS) Details

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase I clinical trials for advanced lymphomas and multiple myeloma; and HER 2-/ ER+ or PR+ breast cancer, and NUT midline carcinoma. It also develops CUDC-427 that is in Phase I clinical trials for advanced solid tumor and lymphomas; programmed death ligand-1 antagonist, which is in preclinical stage for the treatment of cancers; small molecule Interleukin-1 receptor-associated kinase 4 inhibitor that is in preclinical stage for the treatment of hematological cancers; and CUDC-305 drug candidate, which is in trials in patients with systemic mastocytosis and glioblastoma multiforme for the treatment of cancers. In addition, the company offers Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma (BCC). Its Erivedge is also in Phase II clinical trials for preceding excision and/or multiple BCC, and idiopathic pulmonary fibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

35 Employees
Last Reported Date: 02/24/15
Founded in 2000

curis inc (CRIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $464.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $399.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $409.7K
Vice Chairman and Strategic Advisor
Total Annual Compensation: $226.3K
Vice President of Technology Management & Int...
Total Annual Compensation: $230.0K
Compensation as of Fiscal Year 2014.

curis inc (CRIS) Key Developments

Curis, Inc. Presents Preclinical Data on CUDC-427 at AACR Annual Meeting

Curis, Inc. announced data presented from in vitro and in vivo studies for CUDC-427, an antagonist of inhibitor of apoptosis (IAP) proteins, at the American Association for Cancer Research (AACR) 2015 Annual Meeting. CUDC-427 is being studied in a Phase 1 trial in patients with advanced solid tumors or lymphoma. Curis' collaborator, Aurigene Discovery Technologies Limited, also reported preclinical data on its interleukin-1 receptor association kinase-4 (IRAK-4) inhibitor program at AACR. CUDC-427 presentations: Curis scientists presented two CUDC-427 posters at AACR. The first poster, "Predictive biomarker signatures for IAP inhibitor CUDC-427," discussed data from in vitro and in vivo studies that were conducted to identify predictive gene signatures that may be associated with drug response in ovarian and breast cancers. The drug response and genomic/expression profiles of 29 breast and ovarian patient-derived xenografts (PDX) were used to generate a set of gene signatures that will be further validated in additional PDX models and patient samples derived from ongoing clinical testing of CUDC-427. The second poster, "IAP inhibitor CUDC-427 induces tumor regression or stasis in preclinical models of B-cell lymphoma," reported data from in vitro and in vivo studies showing CUDC-427 anti-tumor activity in multiple hematologic cancer models, including diffuse large B-cell lymphoma (DLBCL). Data from a panel of human hematologic cell lines showed that the DLBCL cell lines were most sensitive to CUDC-427 treatment in growth inhibition assays. The anti-tumor effect of CUDC-427 was further confirmed in vivo studies where daily dosing of CUDC-427 induced tumor regression or stasis in certain DLBCL xenograft and B-cell lymphoma syngeneic mouse models. IRAK-4 program presentation: Curis' collaborator Aurigene presented a poster entitled "Novel IRAK-4 inhibitors exhibit highly potent anti-proliferative activity in DLBCL cell lines with activating MYD88 L265P mutation" that included data from multiple chemically distinct series of potent oral IRAK-4 inhibitors. These compounds were shown to potently inhibit IRAK-4 kinase activity in biochemical assays as well as proliferation of MYD88 mutant DLBCL cell lines. Anti-tumor activity in DLBCL was further confirmed in a MYD88 mutant xenograft model. Some of these compounds also significantly reduced disease burden in a rat collagen-induced arthritis model, an in vivo model for inflammation.

Curis, Inc. Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma

Curis, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead proprietary drug candidate, CUDC-907 for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). CUDC-907 is an oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is currently under investigation in Phase 1 clinical studies in patients with relapsed or refractory lymphomas or multiple myeloma as well as in patients with advanced/relapsed solid tumors, including hormone receptor positive (HR+)/HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements. The FDA's Orphan Drug Designation program grants orphan status to drugs and biologics that are intended for use in rare diseases/or disorders, defined as those that affect fewer than 200,000 people in the U.S. or that affect more than 200,000 people in the U.S. where there is no reasonable expectation that the cost of developing and making the drug or biological product for the specific disease or condition will be recovered from sales in the U.S. Orphan drug designation may qualify the sponsor for financial incentives such as tax credits for qualified trials, the ability to apply for annual grant funding, clinical trial research design assistance and waiver of application fees associated with the approval of new drug under the Prescription Drug User Fee Act. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug or biological product for the same indication for a period of 7 years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or if the product with orphan exclusivity experiences a shortage. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

Curis Seeks Acquisitions

Curis, Inc. (NasdaqGM:CRIS) priced its common stock offering resulting in aggregate proceeds of $60 million. Curis will use the proceeds to fund potential acquisitions of new business, technologies or products that it believes complement or expand its business, and for general working capital and capital expenditures.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $2.96 USD -0.01

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $2.12 USD 0.00
CTI BioPharma Corp $1.96 USD +0.01
Cytokinetics Inc $7.25 USD -0.18
Exelixis Inc $3.08 USD -0.02
Navidea Biopharmaceuticals Inc $1.49 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.9x
Price/Book 8.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CURIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at